Altimmune to Present at Two Upcoming Virtual Investor Conferences
H.C. Wainwright Hepatitis B Virus (HBV) Virtual Conference Tuesday, October 20, 2020 –1:30 pm EDT
- B.
Riley Securities – Liver Disease SymposiumThursday, October 29, 2020
The H.C. Wainwright HBV presentation will be webcast and can be accessed by visiting the investor relations section of the company's website at www.altimmune.com under Events / Presentations.
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. The Company’s diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visit www.altimmune.com.
Investor Contacts:
Altimmune, Investor Relations | |
Phone: 410-474-8200 | 617-430-7577 |
sjurchison@altimmune.com | arr@lifesciadvisors.com |
Source: Altimmune, Inc.